Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NKTX
stocks logo

NKTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.303
-13.33%
--
--
-0.313
-27.13%
--
--
-0.320
+3.23%
Estimates Revision
Stock Price
Go Down
down Image
-18.58%
In Past 3 Month
Wall Street analysts forecast NKTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NKTX is 12.33 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast NKTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NKTX is 12.33 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.840
sliders
Low
10.00
Averages
12.33
High
16.00
Current: 1.840
sliders
Low
10.00
Averages
12.33
High
16.00
Stifel
Buy
downgrade
$12 -> $11
2025-11-11
Reason
Stifel
Price Target
$12 -> $11
2025-11-11
downgrade
Buy
Reason
Stifel lowered the firm's price target on Nkarta to $11 from $12 and keeps a Buy rating on the shares. The firm believes management's decision to forego a preliminary year-end 2025 data disclosure and instead guide to the presentation of a more-fulsome data set at a FY26 medical conference should remove a near-term overhang given the former disclosure format was perceived to be mostly inconclusive, the analyst tells investors following the Q3 update.
Stifel
Stephen Willey
Buy
downgrade
$14 -> $12
2025-08-14
Reason
Stifel
Stephen Willey
Price Target
$14 -> $12
2025-08-14
downgrade
Buy
Reason
Stifel analyst Stephen Willey lowered the firm's price target on Nkarta to $12 from $14 and keeps a Buy rating on the shares. The recent earnings announcement and corporate update did not provide "any incremental surprises" as management is still guiding to the disclosure of preliminary data from the Ntrust-1/2 trials evaluating NKX019 in autoimmune disease before year-end, the analyst tells investors. The firm's reduced price target mostly reflects revised longer-term financing assumptions and valuation, the analyst noted.
Mizuho
Outperform -> NULL
downgrade
$16 -> $14
2025-06-10
Reason
Mizuho
Price Target
$16 -> $14
2025-06-10
downgrade
Outperform -> NULL
Reason
Mizuho lowered the firm's price target on Nkarta to $14 from $16 and keeps an Outperform rating on the shares. The firm updated the company's model post the Q1 report. It moderated the near-term ramp and unadjusted peak sales for NKX019, citing the current competitive landscape in autoimmune diseases.
William Blair
William Blair
Outperform -> Market Perform
downgrade
2025-05-15
Reason
William Blair
William Blair
Price Target
2025-05-15
downgrade
Outperform -> Market Perform
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$11
2025-04-09
Reason
Needham
Gil Blum
Price Target
$11
2025-04-09
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$18
2025-03-27
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$18
2025-03-27
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Nkarta Inc (NKTX.O) is -1.45, compared to its 5-year average forward P/E of -4.98. For a more detailed relative valuation and DCF analysis to assess Nkarta Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.98
Current PE
-1.45
Overvalued PE
0.34
Undervalued PE
-10.30

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.47
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.86
Undervalued EV/EBITDA
-4.80

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

NKTX News & Events

Events Timeline

(ET)
2025-11-10
16:04:10
Nkarta Announces Q3 Earnings Per Share of 29 Cents, Below Consensus Estimate of 30 Cents
select
2025-08-12 (ET)
2025-08-12
16:05:27
Nkarta reports Q2 EPS (31c), consensus (35c)
select
2025-06-09 (ET)
2025-06-09
16:15:10
Lyell Immunopharma appoints David Shook as CMO, Mark Meltz as general counsel
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
12-02Globenewswire
Nkarta (NKTX) Participates in Evercore 8th Annual Healthcare Conference to Showcase NK Cell Therapy Progress
  • Conference Participation: Nkarta will participate in the Evercore 8th Annual Healthcare Conference on December 4 in Miami, showcasing its progress in NK cell therapies for autoimmune diseases, which is expected to attract investor and industry attention.
  • Live Webcast: The event is scheduled for 10:50 a.m. ET and will be simultaneously webcast on Nkarta's investor section of its website, allowing global investors to access real-time information.
  • Replay Availability: Following the conference, a replay will be archived on Nkarta's website for approximately 90 days, ensuring that investors who cannot attend live can still access relevant information, thereby enhancing the company's transparency.
  • Company Background: Nkarta focuses on developing allogeneic, off-the-shelf NK cell therapies, combining cell expansion and cryopreservation platforms to provide deep therapeutic activity intended for broad outpatient access, demonstrating its innovative potential in the biopharmaceutical sector.
[object Object]
Preview
1.0
10-31Newsfilter
Nkarta to Attend Investor Conferences in November

  • Investor Conferences Participation: Nkarta, Inc. will participate in the Stifel 2025 Healthcare Conference on November 12 and the TD Cowen's Immunology & Inflammation Summit on November 13, 2025, featuring fireside chats at both events.

  • Webcast Availability: A simultaneous webcast of the events will be available on Nkarta's website, with a replay archived for approximately 90 days.

  • Company Overview: Nkarta is a clinical-stage biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies for autoimmune diseases, utilizing advanced cell engineering and CRISPR technologies.

  • Contact Information: For media and investor inquiries, Nadir Mahmood from Nkarta can be contacted via email at nmahmood@nkartatx.com.

[object Object]
Preview
1.0
10-22Newsfilter
Nkarta to Present Poster at the Upcoming American College of Rheumatology (ACR) Convergence Meeting

  • Nkarta's Presentation at ACR Convergence 2025: Nkarta, Inc. will present clinical data on its investigational therapy NKX019 at the American College of Rheumatology meeting, showcasing its effectiveness in depleting pathogenic B cells in non-Hodgkin lymphoma and autoimmune disease models.

  • Potential of NKX019: The data suggest that NKX019 could serve as a novel therapeutic approach for autoimmune diseases driven by pathological B cells, offering a treatment option with reduced toxicities compared to current therapies.

  • Details of the Presentation: The poster presentation is scheduled for October 26, 2025, from 10:30 AM to 12:30 PM CT, and will be held in Hall F1, focusing on B Cell Biology & Targets in Autoimmune & Inflammatory Disease.

  • Company Overview: Nkarta is a clinical-stage biotechnology company specializing in allogeneic NK cell therapies for autoimmune diseases, aiming to provide accessible outpatient treatment options through advanced cell engineering technologies.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Nkarta Inc (NKTX) stock price today?

The current price of NKTX is 1.84 USD — it has increased 3.37 % in the last trading day.

arrow icon

What is Nkarta Inc (NKTX)'s business?

Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.

arrow icon

What is the price predicton of NKTX Stock?

Wall Street analysts forecast NKTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NKTX is 12.33 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Nkarta Inc (NKTX)'s revenue for the last quarter?

Nkarta Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Nkarta Inc (NKTX)'s earnings per share (EPS) for the last quarter?

Nkarta Inc. EPS for the last quarter amounts to -0.29 USD, decreased -25.64 % YoY.

arrow icon

What changes have occurred in the market's expectations for Nkarta Inc (NKTX)'s fundamentals?

The market is revising No Change the revenue expectations for NKTX for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -18.58%.
arrow icon

How many employees does Nkarta Inc (NKTX). have?

Nkarta Inc (NKTX) has 157 emplpoyees as of December 05 2025.

arrow icon

What is Nkarta Inc (NKTX) market cap?

Today NKTX has the market capitalization of 131.05M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free